Navigation Links
ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis
Date:9/21/2008

fically inhibit the production of VLA-4 could significantly reduce disease activity in RRMS patients as early as 8 weeks. The level of efficacy achieved by ATL/TV1102 is very promising particularly when considering the short duration of dosing within the trial. As an antisense drug ATL/TV1102 will have a different, potentially preferable, safety profile to other drugs that target VLA-4 and therefore presents an exciting future treatment option for RRMS patients."

Mark Diamond, Chief Executive Officer of Antisense Therapeutics, said, "We are delighted to have our ATL/TV1102 Phase IIa trial results presented at such an important scientific meeting on MS. The development of ATL/TV1102 as an MS treatment continues with our partner Teva Pharmaceutical Industries (Teva) and we look forward to the prospect of Teva reporting on ATL/TV1102's future clinical progress. Importantly, the demonstration of significant disease activity with ATL/TV1102 in MS points to the potential of ATL/TV1102 in other disease settings such as autoimmune, inflammation and cancer. It also provides important validation for the application of second-generation antisense drugs outside of cardiovascular and metabolic diseases such as high cholesterol and diabetes where there has been success to date. We believe our results provide important substantiation for the broader clinical application of the second-generation technology."

"We are very encouraged by the data. Not only do they represent promising results for patients with MS, but they also evidence the significant progress we are making in demonstrating the effectiveness, efficiency and the breadth of opportunity of our antisense platform. It's another disease and another tissue where we have great proof-of-concept for antisense drugs," said Stanley Crooke, M.D., Ph.D., Chairman and Chief Executive Officer of Isis. "ATL/TV1102 and ATL's strategic relationship with Teva to move the drug forward further validates our business strategy.
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.; Antisense Therapeutics Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... -- The Assistance Fund announces the addition of its ... for copay to individuals diagnosed with Melanoma. ... the Melanoma Copay Assistance Program to our portfolio of ... "With each additional program we are closer to achieving ... one is denied access to medications due to an ...
(Date:5/22/2015)... -- The North American dental lasers market was ... reach $90.7 million by 2019, at a CAGR of 9.2% ... of North America Dental Lasers Market for an analysis of ... and figures. http://www.micromarketmonitor.com/market/north-america-dental-lasers-1771208223.html ...   Dental lasers are specifically used in oral ...
(Date:5/22/2015)... KING OF PRUSSIA, Pa. , May 22, 2015 /PRNewswire/ ... CSL Behring its 2015 Corporate Leadership Award as recognition ... and improving the care of the bleeding disorders community.  The ... Managing Director, CSL Limited, during the NHF Annual Spring Soiree ... 21. "The National Hemophilia Foundation is dedicated to ...
Breaking Medicine Technology:The Assistance Fund Adds Melanoma Assistance Program 2North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 2North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 3National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 2National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 3National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 4
(Date:5/24/2015)... 25, 2015 Pacific Prime has announced that they ... looking at the cost of individual international health insurance. Titled: ... looks at the cost of health insurance in six top expat ... Hong Kong , Singapore , ... UAE , the UK , Article 2 ...
(Date:5/24/2015)... 2015 Scientists with Cardno ChemRisk, a ... quality compliance issues that may have raised the risk ... has just posted an article on the research. ... group found airborne asbestos levels well above OSHA safety ... and 2011. , “Asbestos compliance sampling data associated with ...
(Date:5/24/2015)... 24, 2015 Medicx Media Solutions ... strategy executive Jay Krihak as its head of ... ramp up its expertise and leadership position in ... and Health sectors. , Krihak is an experienced, ... recently, Krihak led sales planning teams for mobile ...
(Date:5/23/2015)... 2015 Dr. David Benvenuti, an experienced plastic ... a new article to his website that takes ... Benvenuti explained in the fascinating blog, he has recently ... earlobes. , Known as “gauging,” the technique involves placing larger ... Benvenuti said will eventually stretch the holes out to incredible ...
(Date:5/23/2015)... 23, 2015 A live auction will be ... hospitals, surgery centers and other medical facilities around the United ... endoscopy, lab, radiology, surgery, anesthesia, exam and much more. ... and Thursday, May 28 starting at 9:00am CDT each day. ... N. 25th Avenue, Melrose Park, IL 60160. Anyone can ...
Breaking Medicine News(10 mins):Health News:Pacific Prime Releases 2nd Article of Cost of Health Insurance Report 2Health News:New Analysis Finds Too Many Employers Ignored OSHA Asbestos Guidelines, According to Surviving Mesothelioma 2Health News:Medicx Media Solutions Expands Executive Team 2Health News:Dr. Benvenuti, a Plastic Surgeon in Newport Beach, CA, Posts New Article about Repairing Ear Gauges 2Health News:Over 5,200 Lots of Medical Equipment Will Be Sold by Live Auction 2
... implanted in the eye during cataract surgery have led ... a common form// of farsightedness that typically develops in ... School urges people considering this operation to weigh its ... recently developed implantable variable-focus lenses, which enable people to ...
... courthouse in New Jersey was closed following the diagnosis of ... remain shut at// least until Monday. ,State and ... partly due to privacy rules. The woman’s condition has been ... independent title searcher with the Mercer County clerk's office. ...
... Pradesh will soon get calorie-rich and varied midday meals.// ... the state were being served 'khichdi' six times a week ... the menu drab. ,"Now the government has chalked ... vegetables and even an occasional serving of dry fruit," said ...
... seven students at Wheaton College and has caused affected students ... September 7. Mumps causes// swollen glands close to the jaw ... we have a good handle on things, and we are ... for the DuPage County Health Department. "We feel that Wheaton ...
... Pharmaceuticals has announced that exenatide is very effective in ... aspart 30/70 (NovoMix by NovoNordisk). This finding was revealed after ... a boon to people suffering type 2 diabetes and unable ... , ,The study, which spanned a year, ...
... foeticide in Kerala have come as a surprise to politicians ... literacy rate.// ,"The number of girls in the 0-6 ... happened just because of female feticide and nothing else. The ... is happening and who are the guilty," said Health Minister ...
Cached Medicine News:
... modular cleanroom for biological safety labs ... cleanliness (to Class 10/ISO 3) and ... create ultra-smooth surfaces that are easy ... radius corners simplify cleaning. Unique double-wall ...
Inquire...
... want a floor model centrifuge to do, but ... , PR-7000M delivers up to 50% more force ... done faster and more efficiently., Tremendous Capacity ... 6 liters, PR-7000M accommodates 30 microplates, up to ...
Inquire...
Medicine Products: